StockNews.com started coverage on shares of Evoke Pharma (NASDAQ:EVOK – Get Free Report) in a report issued on Thursday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Stock Up 16.8 %
Evoke Pharma stock opened at $0.55 on Thursday. Evoke Pharma has a 12-month low of $0.42 and a 12-month high of $2.42. The business’s 50-day moving average price is $0.63 and its two-hundred day moving average price is $0.93. The stock has a market cap of $4.66 million, a PE ratio of -0.24 and a beta of 0.22.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last released its earnings results on Thursday, March 14th. The specialty pharmaceutical company reported ($0.59) earnings per share (EPS) for the quarter. Evoke Pharma had a negative net margin of 150.43% and a negative return on equity of 517.99%. The business had revenue of $1.68 million during the quarter.
Evoke Pharma Company Profile
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Featured Stories
- Five stocks we like better than Evoke Pharma
- Russell 2000 Index, How Investors Use it For Profitable Trading
- United Airlines Soars on Earnings Beat
- The How and Why of Investing in Gold Stocks
- J.B. Hunt Hits the Skids: Lower Prices to Come
- How to Buy Cheap Stocks Step by Step
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
